The Effects of Ziprasidone 320 mg on Glucose and Plasma Lipids in Patients With Diabetes Type II and Schizophrenia or Schizoaffective Disorder.

Trial Profile

The Effects of Ziprasidone 320 mg on Glucose and Plasma Lipids in Patients With Diabetes Type II and Schizophrenia or Schizoaffective Disorder.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 28 Jul 2011

At a glance

  • Drugs Ziprasidone (Primary)
  • Indications Schizoaffective disorder; Schizophrenia
  • Focus Pharmacodynamics
  • Most Recent Events

    • 28 Jul 2011 Actual initiaion date changed from Jun 2008 to Jan 2010 as reported by ClinicalTrials.gov.
    • 28 Jul 2011 Actual initiaion date changed from Sep 2001 to Sep 2003 as reported by ClinicalTrials.gov.
    • 06 Aug 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top